Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
None USD 0.00(0%)
Last update at 2025-04-14T13:56:27.560148Z
Market Cap
40.55M

Momentum Score

…

Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.28
Low
21.41
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
196.64M
Revenue Per Share
9.86
Gross Profit TTM
139.83M
Debt / Equity
-2.51
ROE
-4447.26%
Net Debt
288.30M
ROCE
-14.77%
Diluted EPS TTM
-7.76

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -80.70M 3.38M -23.41M -12.26M -13.52M
Net income -82.34M 2.06M -23.88M -12.35M -30.77M
Selling general administrative 45.92M 32.95M 31.51M 24.03M 21.00M
Selling and marketing expenses 106.95M 76.76M 52.77M 71.11M 58.42M
Gross profit 139.83M 133.10M 75.77M 98.16M 80.38M
Reconciled depreciation 2.62M 1.34M 1.39M 1.55M 1.21M
Ebit -38.19M -1.29M -22.83M -12.06M -13.39M
Ebitda -38.00M 0.06M -21.43M -10.52M -12.18M
Depreciation and amortization 0.19M 1.34M 1.39M 1.55M 1.21M
Non operating income net other -39.45M - -0.58M -0.20M -0.12M
Operating income -38.19M -1.29M -22.83M -12.06M -13.39M
Other operating expenses 290.59M 229.44M 170.51M 193.78M 176.11M
Interest expense 5.66M 2.51M 0.58M 0.20M 0.88M
Tax provision 1.64M 1.32M 0.47M 0.09M 17.25M
Interest income 2.60M - - 0.20M 0.12M
Net interest income -4.41M -3.22M -0.58M -0.20M -0.12M
Income tax expense 1.64M 1.32M 0.47M 0.09M 17.25M
Total revenue 252.40M 231.27M 147.68M 181.71M 162.72M
Total operating expenses 178.02M 131.28M 98.60M 110.23M 93.77M
Cost of revenue 112.57M 98.17M 71.91M 83.55M 82.34M
Total other income expense net -42.51M 4.67M -0.58M -0.20M -0.12M
Net income from continuing ops -82.34M 2.06M -23.88M -12.35M -30.77M
Net income applicable to common shares -82.34M 2.06M -23.88M -12.35M -30.77M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 346.29M 520.99M 280.29M 132.73M 113.74M
Other current assets 4.04M 24.04M 14.54M 8.78M 5.65M
Total liab 518.12M 536.17M 223.72M 75.85M 67.80M
Total stockholder equity -171.83M -15.18M 56.57M 56.88M 45.94M
Deferred long term liab - - 4.20M 3.40M 3.39M
Other current liab 54.23M 57.45M 54.10M 32.30M 32.31M
Common stock 0.02M 0.02M 0.02M 0.02M 0.01M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.01M
Retained earnings -303.35M -140.51M -58.17M -60.23M -36.36M
Other liab - 1.69M 1.33M 1.75M 3.48M
Good will 1.34M 1.34M 1.34M 1.34M 1.34M
Other assets 0.00M 15.21M 11.65M 22.80M 6.83M
Cash 143.61M 145.92M 164.16M 47.05M 26.32M
Total current liabilities 87.75M 105.84M 73.90M 50.73M 55.85M
Current deferred revenue 10.42M 11.84M 9.49M 9.49M 10.83M
Net debt 288.30M 284.70M -14.02M -21.65M -18.40M
Short term debt 3.27M 2.81M 2.42M 2.26M 0.02M
Short long term debt - - - 3.63M -
Short long term debt total 431.91M 430.62M 150.15M 25.39M 7.91M
Other stockholder equity 131.50M 125.41M 114.72M 117.10M 82.35M
Property plant equipment - 53.20M 17.65M 19.38M 2.82M
Total current assets 269.19M 451.24M 249.66M 106.30M 95.05M
Net tangible assets - -16.52M 55.23M 55.54M 45.94M
Short term investments 0.00M 171.39M 74.05M 0.00M 7.61M
Net receivables 49.43M 45.56M 31.45M 21.96M 21.56M
Long term debt 418.69M 416.46M 134.24M 7.18M -
Inventory 72.10M 63.63M 39.50M 28.51M 33.92M
Accounts payable 19.83M 33.74M 7.89M 6.68M 12.69M
Accumulated other comprehensive income - -0.09M -0.01M - -0.06M
Common stock total equity - 0.02M - 0.02M 0.01M
Retained earnings total equity - -140.51M - -60.23M -36.36M
Non currrent assets other 27.86M 14.62M 10.87M 5.08M 6.41M
Non current assets total 77.11M 69.75M 30.63M 26.44M 18.69M
Capital lease obligations 11.33M 14.16M 15.90M 18.21M 7.91M
Long term debt total - - - - 0.58M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 137.43M -194.18M -0.94M 6.39M 2.01M
Change to liabilities - 26.93M 0.80M -9.02M 9.78M
Total cashflows from investing activities - -194.18M -0.94M 6.39M 1.07M
Net borrowings - 246.34M 137.79M 6.63M -0.65M
Total cash from financing activities -2.57M 242.94M 117.53M 31.30M 1.41M
Change to operating activities - -17.45M 6.56M -6.67M 0.74M
Net income -162.83M -82.34M 2.06M -23.88M -12.35M
Change in cash -3.01M -18.24M 117.82M 20.73M 0.26M
Begin period cash flow 146.62M 164.86M 47.05M 26.32M 26.05M
End period cash flow 143.61M 146.62M 164.86M 47.05M 26.32M
Total cash from operating activities -137.87M -67.00M 1.24M -16.96M -2.22M
Issuance of capital stock - 0.00M 0.00M 28.80M -
Depreciation 10.72M 2.62M 1.34M 1.39M 1.55M
Other cashflows from investing activities - - - 0.03M 0.04M
Dividends paid - 56.68M 13.37M 3.43M 2.06M
Change to inventory 15.57M -35.00M -10.94M 5.41M -5.91M
Change to account receivables -4.94M -15.90M -9.57M -2.55M -2.51M
Sale purchase of stock -3.30M -56.68M -16.13M -3.43M -0.83M
Other cashflows from financing activities -3.30M 343.19M 131.36M 6.44M -0.83M
Change to netincome - 51.52M 8.41M 15.87M 10.58M
Capital expenditures 33.01M 22.70M 1.01M 1.28M 0.99M
Change receivables - -15.90M - -2.55M -2.51M
Cash flows other operating - -15.46M - -2.89M -4.73M
Cash and cash equivalents changes - -18.24M - 20.73M 0.26M
Change in working capital -11.20M -42.05M -10.86M -11.37M -4.92M
Stock based compensation 8.06M 14.40M 13.17M 10.11M 9.83M
Other non cash items 51.10M 40.19M -4.35M 7.01M 3.63M
Free cash flow -170.88M -89.69M 0.22M -18.23M -3.21M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ABT
Abbott Laboratories
-0.20
0.19%
103.00 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-0.59
0.59%
100.02 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-
-%
310.00 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-
-%
48.34 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Cutera Inc

Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

3240 Bayshore Boulevard, Brisbane, CA, United States, 94005

415 657 5500

430

Name Title Year Born
Mr. J. Daniel Plants Exec. Chairman 1967
Mr. David H. Mowry CEO & Director 1962
Mr. Rohan R. Seth Chief Financial Officer 1978
Dr. Michael A. Karavitis Ph.D. Exec. VP & Chief Technology Officer 1970
Mr. Charles G. Thier Chief Information Officer 1963
Anne Werdan Director of Investor Relations NA
Dr. Michael A. Karavitis Ph.D. Executive VP & Chief Technology Officer 1970
Mr. Taylor C. Harris President, CEO & Director 1976
Mr. Stuart Drummond Interim Chief Financial Officer NA
Mr. Jeffrey S. Jones Chief Operating Officer 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…